Insider buying last 90 days
No open-market insider purchases were filed for CBT in the last 90 days.
From Form 4 filings, dated to when each was filed.
Cabot's week centered on fiscal fourth-quarter results, with adjusted EPS of $1.61 beating estimates and sales rising 12.24% to $1.009 billion, lifted by strength in Performance Chemicals. Full fiscal 2026 adjusted EPS came in at $6.42, with cash flow of $421 million and $243 million returned to shareholders, alongside mention of a reinforcing carbon facility acquisition in Mexico and investment in battery materials capacity. Offsetting this, Reinforcement Materials showed a 25.4% drop in full-year operating profit, tied to lower gross profit per tonne and a less favorable regional product mix, even as sales ticked up slightly.
Shares closed at $71.85, up 1.1% on the day, but sitting below both the 50-day average of $76.62 and the 200-day average of $79.57, with the 50-day below the 200-day. Over the past month the stock is down 4.1%, and over three and six months it has declined 17.4% and 15% respectively, though it remains up 21.1% over the past year. The GekkoIndex reads 62.6, placing it in the Accumulation zone, and the price sits 33.5% below Gekko Fair Value of $108.
The next earnings date falls on 2 February 2027, 84 days out and beyond a typical 20-trading-day hold. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. Seasonality has been a headwind here, with the next 20 trading days averaging a 2.2% decline over 5 years, rising in only 2 of them. Analyst consensus among 4 firms stands at 2 buy and 2 hold ratings, with a consensus target of $87.67.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Cabot scores 4 supportive, 0 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive0 mixed1 headwind
Below 50 and 200-day
Close $71.92 is below the 50-day ($75.84) and 200-day ($79.58) averages, and the 50-day is below the 200-day.
See the chart62.6, Accumulation
Reading 62.6 is in the Accumulation zone.
See the GekkoIndex31.1% below
Price is 31.1% below Gekko Fair Value (more than 5% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 79 days
Next report Feb 2, 2027, 79 days away — outside a typical 20-trading-day hold.
See earnings+0.3% on average
From this point in the calendar, the next 20 trading days averaged +0.3% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Cabot closed at $71.92 on Nov 13, 2026, +17.0% over the past year, inside a 52-week range of $58.33 to $94.53.
Use the left and right arrow keys to read daily values.
Put CBT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Cabot makes specialty chemicals and performance materials, with a strong focus on carbon-based products. It is best known for reinforcing carbons that strengthen rubber in tires and in industrial goods like hoses, belts, and molded parts, alongside engineered elastomer composites. Its broader catalog includes specialty carbons for inks, coatings, plastics, and batteries, plus fumed silica and fumed alumina used in adhesives, cosmetics, coatings, and battery components for electric vehicles.
The company is structured around two segments, Reinforcement Materials and Performance Chemicals, which together cover its carbon and specialty additive lines. Additional offerings include aerogel insulation particles, masterbatch and conductive compounds for automotive, packaging, and electronics uses, inkjet colorants, carbon nanotubes, and fumed metal oxides. Cabot reaches customers through distributors and sales representatives across the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Cabot traces its founding to 1882 and is headquartered in Boston, Massachusetts. Its shares are listed on the NYSE under the ticker CBT.
Cabot’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 62.6, in the Accumulation zone, down 0.8 points over five sessions.
Down 0.8 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 52 | +0.6% | −0.8% | ||
| Accumulation (current zone) | 249 | −0.3% | −1.7% | ||
| Neutral | 375 | +0.3% | +1.5% | ||
| Distribution | 25 | −0.7% | +1.7% | ||
| Selling | 1 | Too few readings yet | |||
Average CBT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
Cabot trades 31.1% below Gekko Fair Value of $104.43, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Cabot shares are worth, recalculated every trading day.
$104.43
Gekko Fair Value, Nov 14, 2026
31.1% Undervalued
At the end of Sep 2026 the price was 23.4% below the estimate.
No open-market insider purchases were filed for Cabot, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for CBT in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in CBT were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Cabot has been buying back its own shares.
From company filings.
Cabot reports on Feb 2, 2027, before the open (79 days away), and beat the EPS estimate in 7 of its last 8 reports.
Feb 2, 2027
Expected before the open, 79 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Feb 3, 2026 | $1.53 est $1.40 | $849.0M est $887.0M | +8.1% |
| Nov 3, 2025 | $1.70 est $1.68 | $899.0M est $930.0M | −9.2% |
| Aug 4, 2025 | $1.90 est $1.82 | $923.0M est $977.6M | +11.2% |
| May 5, 2025 | $1.90 est $1.85 | $936.0M est $955.0M | −7.1% |
| Feb 3, 2025 | $1.76 est $1.77 | $955.0M est $1.03B | +2.0% |
| Nov 4, 2024 | $1.80 est $1.79 | $1.00B est $1.01B | −0.1% |
| Aug 5, 2024 | $1.92 est $1.72 | $1.02B est $1.00B | +12.6% |
| May 6, 2024 | $1.78 est $1.66 | $1.02B est $1.04B | +7.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Cabot is $85.33, +18.6% from the last close, from 5 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 5 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 10 | J.P. Morgan | $68 | −5.5% |
| Nov 4 | Truist Financial | $95 | +32.1% |
| Nov 4 | UBS | $80 | +11.2% |
| Nov 3 | Mizuho Securities | $85 | +18.2% |
| Oct 5 | UBS | $86 | +19.6% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Cabot averaged +0.3% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.7% | 2 of 5 |
| Next 10 trading days | −2.6% | 1 of 5 |
| Next 15 trading days | −1.9% | 1 of 5 |
| Next 20 trading days | +0.3% | 3 of 5 |
| Next 30 trading days | −2.9% | 2 of 5 |
For scale, CBT’s typical 20-trading-day move in either direction is about 5.8%.
Cabot’s market cap is $3.69B, with a P/E ratio of 18 and revenue of $3.74B over the last twelve months.
Coverage of Cabot this week reads neutral: 1 positive, 7 neutral and 0 negative headlines.
Cabot’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LINLinde | Neutral | 4.8% above |
| ECLEcolab | Neutral | 16.6% above |
| APDAir Products and Chemicals | Neutral | 0.5% above |
| DOWDow | Neutral | 23.9% below |
| LYBLyondellBasell Industries | Neutral | 6.5% below |
| ALBAlbemarle | Accumulation | 20.7% below |
A peer links to its own page where one exists.
Cabot’s market cap is $3.69B at the Nov 13, 2026 close of $71.92, with 51.34M shares outstanding. The shares trade on a P/E ratio of 18.
The consensus analyst 12-month price target for Cabot is $85.33, +18.6% from the last close. Of the 5 firms that rated the stock in the last 90 days, 2 rate it a buy, 2 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Cabot is undervalued: the Nov 13, 2026 close of $71.92 is 31.1% below Gekko Fair Value of $104.43. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Cabot is expected to report on Feb 2, 2027, before the market opens (79 days away). Analysts expect earnings of $1.42 per share on revenue of $866.5M. Cabot beat the earnings estimate in 7 of its last 8 reports, moving 7.2% on average across the report.
Cabot’s 52-week high is $94.53 and its 52-week low is $58.33; it closed at $71.92 on Nov 13, 2026, +17.0% over the past year. Over the last five years the shares peaked at $117.46 on Nov 7, 2024.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality) and 1 as a headwind (trend). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.